Abstract:Aptamers, also known as chemical antibodies, are short single-stranded DNA, RNA or peptide molecules. These molecules can fold into complex three-dimensional structures and bind to target molecules with high affinity and specificity. The nucleic acid aptamers are selected from combinatorial libraries by an iterative in vitro selection procedure known as systematic evolution of ligands by exponential enrichment (SELEX). As a new class of therapeutics and drug targeting entities, bivalent and multivalent aptamer-based molecules are emerging as highly attractive alternatives to monoclonal antibodies as targeted therapeutics. Aptamers have several advantages, offering the possibility of overcoming limitations of antibodies: 1) they can be selected against toxic or non-immunogenic targets; 2) aptamers can be chemically modified by using modified nucleotides to enhance their stability in biological fluids or via incorporating reporter molecules, radioisotopes and functional groups for their detection and immobilization; 3) they have very low immunogenicity; 4) they display high stability at room temperature, in extreme pH, or solvent; 5) once selected, they can be chemically synthesized free from cell-culture- derived contaminants, and they can be manufactured at any time, in large amounts, at relatively low cost and reproducibly; 6) they are smaller and thus can diffuse more rapidly into tissues and organs, leading to faster targeting in drug delivery; 7) they have lower molecular weight that can lead to faster body clearance, resulting in a low background noise for imaging and minimizing the radiation dose to the patient in diagnostic imaging. Thus, the high selectivity and sensitivity, ease of screening and production, chemical versatility as well as stability make aptamers a class of highly attractive agents for the development of novel therapeutics, targeted drug delivery vehicles and molecular imaging. In the review, we will discuss the latest technological advances in developing aptamers, its application as a novel class of drug on its own, as well as in surface functionalization of both polymer nanoparticles or nanoliposomes in the treatment of cancer, viral and autoimmune diseases.

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

Smart ligand: Aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy

Aptamer Mediated Delivery of Small Interfering RNAs

Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras

Aptamer Therapeutics: The 21st Century`s Magic Bullet of Nanomedicine

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Advances in the Development of Aptamer Drug Conjugates for Targeted Drug Delivery.

Synthetic SiRNA Delivery: Progress and Prospects

Recent advances in aptamer-based targeted drug delivery systems for cancer therapy

Aptamer and Aptamer Pharmaceuticals

Nucleic acids based integrated macromolecular complexes for SiRNA delivery: Recent advancements

Advances In The Development Of Aptamer Drug Conjugates For Targeted Drug Delivery

Current Development of siRNA Bioconjugates: From Research to the Clinic

Gene therapy progress and prospects: RNA aptamers

Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery

Developments in siRNA Modification and Ligand Conjugated Delivery To Enhance RNA Interference Ability

Recent Progress In Aptamer Discoveries And Modifications For Therapeutic Applications

A Universal Protein Tag for Delivery of SiRNA-Aptamer Chimeras

Recent Progress and Opportunities for Nucleic Acid Aptamers

Molecular Aptamers for Drug Delivery

Oligonucleotide delivery: a patent review (2010 – 2013)